万赛维哪产的？

(Valganciclovir hydrochloride) is an oral anti-cytomegalovirus infection drug developed by the Swiss company Roche. It was approved by the US FDA in May 2001. It is clinically used to treat acute retinitis caused by CMV infection in patients with acquired immunodeficiency syndrome. In May 2003, its indications were expanded to prevent and treat secondary CMV infection in organ transplant recipients.

Valganciclovir hydrochloride is administered orally and should be taken with food. Valganciclovir (valganciclovir hydrochloride) is rapidly and extensively converted into ganciclovir. The absolute bioavailability of Valganciclovir (valganciclovir hydrochloride) as measured by ganciclovir is 10 times higher than that of ganciclovir capsules, so the dosage and usage instructions of Valganciclovir (valganciclovir hydrochloride) should be strictly followed. And use it under the guidance of doctors and pharmacists.

When Valganciclovir hydrochloride is used to prevent CMV infection in adult patients after organ transplantation, the recommended dose for kidney transplant patients is 900 mg (two 450 mg tablets) once daily, starting within 10 days after transplantation and continuing until 200 days after transplantation. For patients who have received a solid organ transplant other than a kidney, the recommended dose is 900 mg (two 450 mg tablets) once daily, starting within 10 days after transplantation and continuing until 100 days after transplantation.

Pregnant and lactating women: Due to the rapid and large-scale conversion of valganciclovir into ganciclovir, studies on its reproductive toxicity have not been repeated. In animal experiments, ganciclovir caused reduced fertility and teratogenic effects. It is recommended that women of childbearing potential use effective contraceptive measures during treatment. Male patients are advised to use barrier contraception during treatment with valganciclovir hydrochloride tablets and for at least 90 days after discontinuation of treatment.

There are no safety data on valganciclovir hydrochloride tablets during human pregnancy. Pregnant women should avoid the use of valganciclovir hydrochloride tablets unless the benefits to the mother far outweigh the potential harm to the fetus.

The developmental effects of valganciclovir or cyclovir on perinatal and postnatal infants have not been studied, but it must be considered that ganciclovir may be excreted in breast milk and cause serious adverse reactions in infants. Therefore, a decision should be made to discontinue medication or discontinue breastfeeding when considering the possible benefits of valganciclovir hydrochloride to the nursing mother.